The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
about
Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsTiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial AsthmaOnce-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacyLong-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerationsA review of nebulized drug delivery in COPDTiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.Advances in device and formulation technologies for pulmonary drug delivery.Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesTesting two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial resultsTiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease.Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary diseaseClinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devicesMuscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD.Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switchCardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.Safety and tolerability of inhalational anticholinergics in COPDThe Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationaleTiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study.Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler.Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.Opportunities in respiratory drug delivery.TIOtropium Safety and Performance In Respimat (TIOSPIR): Analysis of Asian cohort of COPD patients.Long-acting muscarinic antagonists.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.Tiotropium formulations and safety: a network meta-analysisSafety of inhaled long-acting anti-muscarinic agents in COPD.Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical TrialsThorax editorial by Jenkins and Beasley related to tiotropium respimat.A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products
P2860
Q24613889-616500FE-4AD4-461B-BE9B-300DAFCF656BQ26780553-9C0ED7EA-EBC5-48A3-A95A-FC818513AE89Q27010444-F4A0E7C1-F613-45AF-8197-E2F3C0452547Q28067579-EB7B9215-1029-4F1E-A6A1-BCE2FAC7BFDEQ28075295-4206B653-DC7D-4C73-BA44-0D1E462B80A2Q30620671-56E7DB8A-5113-479D-B238-E5419E11EC18Q30820402-D0FAF4CF-D096-4440-8365-34F14F9026EBQ30877371-4E472A72-799E-49E6-AC95-3F376F79790BQ33962567-1AEA6344-FDF2-4E32-8A86-FB32D7581BBEQ34065963-35E72C84-3EED-4D79-BC32-07690760DC5BQ34133948-CF0FEB85-B1EA-47B0-AE73-246E4FC437F4Q34309072-50EB5D86-F001-418F-8F9F-71B96A5EDB88Q34677811-F7426494-A616-4D8D-91E6-D0F8AE383473Q34721292-7A06F73C-47E9-4BB9-93AB-EBBD625BA1F9Q34903093-461F2575-2E30-441D-B2BF-4A69AA140AEDQ34944616-44306F4A-C104-4904-86D1-6AC3AD40FD64Q35762406-DB092A63-F5F4-425A-B851-8560027728A4Q36680246-DFE14C94-3D40-4E15-9311-6C81A6789E88Q36752114-48159578-F066-4F49-B9EF-72EA7B3D4557Q36802125-AE5D6494-4A7F-490A-91B9-EBCB33451065Q37355305-DB14C400-E0EF-404B-AC7D-70ECC904E246Q37392356-BDC7F21C-66D6-44CA-81B1-4B632817F971Q37667100-720D8BCE-ABC8-46C5-8D0D-4F29B558CFD1Q37701125-C14260B5-5AB3-417E-AABF-58912BAC1518Q38199533-094C47B8-EA34-4A11-8BA4-19182F166745Q38258538-6E2B4939-AE4E-451C-B331-ACCFCE652E2CQ38297120-655CDFDE-C7BB-45F6-8894-EEF642ECFE85Q38411864-1EFC6739-EC7C-4520-B062-1250AF9BC5D4Q38537326-DD55FA6A-DABC-4F23-BC47-05AD6C15A219Q38592062-D401A0FE-0B49-4593-A8D1-436C8D51B964Q38639661-E0DBF65C-D36B-47FA-96BF-F4823267EA01Q39137733-D57A8242-3DA1-4A49-A9B0-5B1A10C29F67Q39232425-327E122A-A200-4277-BE3D-68C2E7D8F8A7Q39846504-99DF588F-08CD-40CE-A542-40AD337DF5E7Q43800626-5919089C-F9D0-4E23-9ED7-68CEB554BE04Q45930166-EBC44E17-D8BB-42AA-9082-30D2FEA66C97Q58869538-B6178757-7BEC-46BD-B8D1-3CECC693F280
P2860
The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The efficacy of tiotropium adm ...... r HandiHaler in COPD patients.
@en
The efficacy of tiotropium adm ...... r HandiHaler in COPD patients.
@nl
type
label
The efficacy of tiotropium adm ...... r HandiHaler in COPD patients.
@en
The efficacy of tiotropium adm ...... r HandiHaler in COPD patients.
@nl
prefLabel
The efficacy of tiotropium adm ...... r HandiHaler in COPD patients.
@en
The efficacy of tiotropium adm ...... r HandiHaler in COPD patients.
@nl
P2093
P1433
P1476
The efficacy of tiotropium adm ...... r HandiHaler in COPD patients.
@en
P2093
J A van Noord
J-L Aumann
P J G Cornelissen
P356
10.1016/J.RMED.2008.10.002
P577
2008-11-20T00:00:00Z